Testing, treatment, side effects, and more.
Posted on: Jul 29, 2021 02:43PM - edited Jul 29, 2021 02:51PM by Moderators
The DESTINY-Breast05 trial is enrolling people diagnosed with HER2-positive breast cancer without a pathologic complete response from treatment before surgery.
The trial is looking to see whether fam-trastuzumab-deruxtecan-nxki reduces recurrence risk more than Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) when given after surgery for HER2-positive breast cancer that didn't have pCR.
Fam-trastuzumab-deruxtecan-nxki is given by intravenous infusion, which means the medicine is delivered directly into your bloodstream through an IV or a port. The medicine is usually given once every 3 weeks.
People are eligible for the DESTINY-Breast05 trial if:
The DESTINY-Breast05 trial is being conducted at multiple sites around the world and the United States. For a complete list of sites, visit https://clinicaltrials.gov/ct2/show/NCT04622319.
For more information on detailed eligibility requirements or to enroll https://www.breastcancer.org/treatment/clinical_trials/featured#destiny5